Drug Profile
Ribavirin oral - Tech Manage Corporation
Latest Information Update: 04 Sep 2023
Price :
$50
*
At a glance
- Originator Nagoya University
- Class Antivirals; Furans; Ribonucleosides; Small molecules; Triazoles
- Mechanism of Action Factor VII stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Haemophilia
Most Recent Events
- 04 Sep 2023 Discontinued - Preclinical for Haemophilia in Japan (PO)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Haemophilia in Japan (PO)
- 06 Jul 2016 Ribavirin oral - Tech Manage Corporation is available for licensing as of 06 Jul 2016. http://www.tech-manage.co.jp